Tenaya Therapeutics, Inc. (TNYA) — 10-Q Filings
All 10-Q filings from Tenaya Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Tenaya Narrows Losses, Boosts Cash Amid R&D Streamlining
— Nov 10, 2025 Risk: medium
Tenaya Therapeutics, Inc. reported a net loss of $20.275 million for the three months ended September 30, 2025, a 20.8% improvement from the $25.634 million net -
Tenaya Narrows Q2 Loss, Boosts Cash with $100M Offering
— Aug 6, 2025 Risk: high
Tenaya Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company experience -
Tenaya Therapeutics Files Q1 2025 10-Q
— May 7, 2025 Risk: medium
Tenaya Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various agreements and events, including an At-The-Market Sale -
Tenaya Therapeutics Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
Tenaya Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the three months e -
Tenaya Therapeutics Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Tenaya Therapeutics, Inc. filed its Q2 2024 10-Q report on August 8, 2024, detailing its financial position as of June 30, 2024. The company, focused on biologi -
Tenaya Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: medium
Tenaya Therapeutics, Inc. (TNYA) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Tenaya Therapeutics, Inc. filed a 10-Q report for the period endi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX